The long-term outlook (5-8% revenue CAGR, 8.5-11.5% EPS CAGR) is in line with the company's historical performance and provides a clear framework for valuation. Monitor upcoming quarterly results for execution against the 2026 guidance and any updates on M&A pipeline or LaunchPad savings. The stock has outperformed the S&P 500 Healthcare index since the prior Investor Day (144% vs 88% TSR), suggesting elevated expectations are already priced in.
LH drugs
LH drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 11 $311.54entry
- T+1 · 2mo ago +1.21%α +1.66% · $315.31
- T+5 · 2mo ago +2.94%α +3.16% · $320.71
- T+20 · 6w ago +0.20%α −1.67% · $312.15
- T+46 · todayOpen
- T+60 · in 20d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Labcorp held its 2026 Investor Day, reaffirming full-year 2026 guidance and providing a long-term outlook through 2029. The company targets 5%-8% compound annual revenue growth and 8.5%-11.5% adjusted EPS CAGR, driven by specialty diagnostics, technology, and M&A. The filing is a routine strategic update with no new financial data beyond previously issued guidance.
Key Facts
- Reaffirmed FY2026 guidance: Enterprise revenue $14.71B-$14.83B (+5.4% to +6.3% YoY), Adjusted EPS $18.10-$18.55 (+10.1% to +12.8% YoY), Free Cash Flow $1.24B-$1.36B.
- Long-term outlook (2026-2029): 5%-8% revenue CAGR, 75-150 bps adjusted operating margin expansion by end of 2029, 8.5%-11.5% adjusted EPS CAGR.
- Organic revenue growth target of 3.5%-5.5% CAGR, with M&A contributing an additional 1.5%-2.5% CAGR.
- Diagnostics segment revenue grew from $9.4B in 2023 to $11.5B at 2026 guidance midpoint (7% CAGR).
- Biopharma Laboratory Services revenue grew from $2.8B in 2023 to $3.3B at 2026 guidance midpoint (6% CAGR).
- Capital deployment from 2023-2025: $6.1B total, with $3.7B reinvested in the business ($1.4B CapEx, $2.3B M&A) and $2.4B returned to shareholders ($0.7B dividends, $1.7B share repurchases).
- LaunchPad productivity savings targeted at $125M-$150M per year.
- Financial leverage target: 2.5x to 3.0x gross debt to TTM adjusted EBITDA.
- Specialty diagnostics (oncology, neurology, autoimmune, women's health) generating $2B in annual revenue with strong growth rates.
- Over 30 M&A deals from 2023-2025 contributed $900M in acquired revenue.
Financial Impact
Reaffirmed FY2026 guidance: Enterprise revenue $14.71B-$14.83B, Adjusted EPS $18.10-$18.55, Free Cash Flow $1.24B-$1.36B. Long-term targets: 5%-8% revenue CAGR, 8.5%-11.5% adjusted EPS CAGR through 2029.
Risk Factors
- Potential impact of PAMA (Protecting Access to Medicare Act) on diagnostics reimbursement.
- Foreign exchange headwinds (0.4% impact on enterprise revenue, 1.5% on BLS).
- Execution risk on M&A integration and achieving targeted 1.5%-2.5% acquisition revenue CAGR.
- Macroeconomic pressures and inflation affecting healthcare utilization.
- Competition from hospital labs and other independent lab providers.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000920148-26-000201 |
| Document: formpr091026ex991investord.htm | 0000920148-26-000201 |
| Document: lh-20260910.htm | 0000920148-26-000201 |
| Document: 0000920148-26-000201-index-headers.html | 0000920148-26-000201 |
| Document: 0000920148-26-000201-index.html | 0000920148-26-000201 |
| Document: 0000920148-26-000201.txt | 0000920148-26-000201 |
Track record
29 reports on LH
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.60% at T+60 after the Apr 30, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $372.32 Now $372.46 +0.04% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $372.23 Now $372.46 +0.06% settles Nov 18
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $363.30 to $372.32 Now $372.46 +2.52% ▲ +2.48% −0.81% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 4, 202612d ago 8-K Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $353.92 to $370.88 Now $372.46 +5.24% ▲ +4.79% +5.38% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $361.39 to $366.57 Now $372.46 +3.06% ▲ +1.43% +4.14% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $360.25 to $367.79 Now $372.46 +3.39% ▲ +2.09% +2.81% vs SPY
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $329.90 to $361.39 Now $372.46 +12.90% ▲ +9.55% +10.81% vs SPY
- Oct 21, 202626d ago 8-K Neutral 2/10 Entry $323.75 to $331.17 Now $372.46 +15.05% ▲ +2.29% +2.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers